Skip to main content
AAN.com
Articles
December 11, 2006

Differences in neuropathologic characteristics across the Lewy body dementia spectrum

December 12, 2006 issue
67 (11) 1931-1934

Abstract

Background: The objective of this comparative neuropathologic study was to determine the extent to which dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are distinct entities or part of a continuum with respect to the duration of parkinsonism.
Methods: We evaluated the relationship between cortical α-synuclein pathology, plaques (Consortium to Establish a Registry for Alzheimer's Disease [CERAD]), tangles (Braak staging), and cholinergic deficits (choline acetyltransferase in temporal cortex) in 57 prospectively assessed patients (29 DLB, 28 PDD), confirmed at autopsy. The PDD group was divided according to the median duration of parkinsonism prior to dementia.
Results: There was an association between longer duration of parkinsonism prior to dementia and less severe cortical α-synuclein pathology (χ2 10.4, df 2, p = 0.006) and lower CERAD plaque scores (χ2 26.6, df 9, p = 0.002), but not Braak staging. These findings were confirmed in a further correlation analysis, which also identified an unexpected correlation between more pronounced cortical cholinergic deficits and longer duration of parkinsonism prior to dementia (R = −0.37, p = 0.04).
Conclusion: While there is a clear relationship between the duration of Parkinson disease prior to the onset of dementia and key neuropathologic and neurochemical characteristics, there is a gradation of these differences across the dementia with Lewy bodies/Parkinson disease dementia spectrum and the findings do not support an arbitrary cut-off between the two disorders.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
2.
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005;65:1863–1872.
3.
Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229–237.
4.
Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137–145.
5.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33–39.
6.
Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? Parkinsonism Relat Disord 2005; 11(suppl 1):S47–51.
7.
Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102–112.
8.
Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol 1999;45:601–610.
9.
Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000;54:407–411.
10.
Aarsland D, Perry R, Brown A, et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773–776.
11.
Richard IH, Papka M, Rubio A, Kurlan R. Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002;17:1161–1165.
12.
Iseki E. Dementia with Lewy bodies: reclassification of pathological subtypes and boundary with Parkinson's disease or Alzheimer's disease. Neuropathology 2004;24:72–78.
13.
Tam CW, Burton EJ, McKeith IG, et al. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005;64:861–865.
14.
Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391–403.
15.
Perry RH, Irving D, Blessed G, et al. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119–139.
16.
Perry E, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarities to Parkinson's and distinctions from Alzheimer's disease. Alzheimer Dis Assoc Disord 1993;7:69–79.
17.
Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538–542.
18.
Larsen JP, Dupont E, Tandberg E. Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242–251.
19.
Fahn S, Elton R, Committee Mot UD. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Goldstein M, Calne D, eds. Recent developments in Parkinson's disease. New York: Macmillan, 1987:153–163.
20.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
21.
Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479–486.
22.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259.
23.
Perry RH, Jaros E, Hall RA, et al. Proposal for modification of consensus guidelines for the neuropathological diagnosis of dementia with Lewy bodies (DLB) when using alfa-synuclein IHC. Third International Workshop on Dementia with Lewy Bodies and Parkinson's Disease. Dementia. Vol. 158. Newcastle upon Tyne, UK, 2003;158.
24.
Lippa SM, Lippa CF, Mori H. Alpha-synuclein aggregation in pathological aging and Alzheimer's disease: the impact of beta-amyloid plaque level. Am J Alzheimers Dis Other Dement 2005;20:315–318.
25.
Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211.
26.
Katsuse O, Iseki E, Marui W, Kosaka K. Developmental stages of cortical Lewy bodies and their relation to axonal transport blockage in brains of patients with dementia with Lewy bodies. J Neurol Sci 2003;211:29–35.
27.
Yamamoto R, Iseki E, Marui W, et al. Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. Neuropathology 2005;25:188–194.
28.
Rodrigo J, Fernandez P, Bentura ML, et al. Distribution of catecholaminergic afferent fibres in the rat globus pallidus and their relations with cholinergic neurons. J Chem Neuroanat 1998;15:1–20.
29.
Torres EM, Rogers DC, Annett LE, et al. A novel population of tyrosine hydroxylase immunoreactive neurones in the basal forebrain of the common marmoset (Callithrix jacchus). Neurosci Lett 1993;150:29–32.

Information & Authors

Information

Published In

Neurology®
Volume 67Number 11December 12, 2006
Pages: 1931-1934
PubMed: 17159096

Publication History

Published online: December 11, 2006
Published in print: December 12, 2006

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

C. Ballard, MRCPsych
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.
I. Ziabreva, PhD
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.
R. Perry, FRCPath
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.
J. P. Larsen, MD
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.
J. O'Brien, FRCPsych
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.
I. McKeith, FRCPsych
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.
E. Perry, DSc
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.
D. Aarsland, MD
From the Wolfson Centre for Age-Related Diseases (C.B.), Wolfson Building, Guy's Campus, King's College London, UK; Institute of Ageing and Health (I.Z., R.P., J.O., I.M., E.P.), Newcastle General Hospital, Newcastle upon Tyne, UK; and Norwegian Center for Movement Disorders (J.P.L., D.A.), Stavanger University Hospital, Stavanger, Norway.

Notes

Address correspondence and reprint requests to Dr. Ballard, Wolfson Centre for Age-Related Diseases, Wolfson Building, Guy's Campus, King's College London, London, SE1 1UL, UK; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Kisspeptin-10 Mitigates α-Synuclein-Mediated Mitochondrial Apoptosis in SH-SY5Y-Derived Neurons via a Kisspeptin Receptor-Independent Manner, International Journal of Molecular Sciences, 24, 7, (6056), (2023).https://doi.org/10.3390/ijms24076056
    Crossref
  2. A Preliminary Comparison of the Methylome and Transcriptome from the Prefrontal Cortex Across Alzheimer’s Disease and Lewy Body Dementia, Journal of Alzheimer's Disease Reports, 7, 1, (279-297), (2023).https://doi.org/10.3233/ADR220114
    Crossref
  3. Comparison of univariate and multivariate analyses for brain [18F]FDG PET data in α-synucleinopathies, NeuroImage: Clinical, 39, (103475), (2023).https://doi.org/10.1016/j.nicl.2023.103475
    Crossref
  4. Elucidating distinct molecular signatures of Lewy body dementias, Neurobiology of Disease, 188, (106337), (2023).https://doi.org/10.1016/j.nbd.2023.106337
    Crossref
  5. Striatal dopamine transporter binding differs between dementia with Lewy bodies and Parkinson’s disease with dementia, Journal of the Neurological Sciences, 451, (120713), (2023).https://doi.org/10.1016/j.jns.2023.120713
    Crossref
  6. Biomarkers in Parkinson’s disease: A state of the art review, Biomarkers in Neuropsychiatry, 9, (100074), (2023).https://doi.org/10.1016/j.bionps.2023.100074
    Crossref
  7. Dementia: A journey from cause to cure, Nanomedicine-Based Approaches for the Treatment of Dementia, (37-56), (2023).https://doi.org/10.1016/B978-0-12-824331-2.00011-X
    Crossref
  8. Involvement of ApoE4 in dementia with Lewy bodies in the prodromal and demented stages: evaluation of the Strasbourg cohort, GeroScience, (2023).https://doi.org/10.1007/s11357-023-00883-6
    Crossref
  9. Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer’s Disease, International Journal of Molecular Sciences, 23, 12, (6371), (2022).https://doi.org/10.3390/ijms23126371
    Crossref
  10. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson’s disease, Frontiers in Aging Neuroscience, 14, (2022).https://doi.org/10.3389/fnagi.2022.1061096
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share